This study demonstrates the involvement of the MT 2 (Mel 1b ) melatonin receptor in mediating phase advances of circadian activity rhythms by melatonin. In situ hybridization histochemistry with digoxigenin-labeled oligonucleotide probes revealed for the first time the expression of mt 1 and MT 2 melatonin receptor mRNA within the suprachiasmatic nucleus of the C3H/HeN mouse. Melatonin (0.9 to 30 mg/mouse, s.c.) administration during 3 days at the end of the subjective day (CT 10) to C3H/HeN mice kept in constant dark phase advanced circadian rhythms of wheel running activity in a dose-dependent manner [EC 50 Å0.72 mg/mouse; 0.98{0.08 h (nÅ15) maximal advance at 9 mg/mouse]. Neither the selective MT 2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 m/mouse, s.c.) nor luzindole (300 mg/mouse, s.c.), which shows 25-fold higher affinity for the MT 2 than the mt 1 subtype, affected the phase of circadian activity rhythms when given alone at CT 10. All three antagonists, however, shifted to the right the dose-response curve to melatonin, as they significantly reduced the phase shifting effects of 0.9 and 3 mg melatonin. This is the first study to demonstrate that melatonin phase advances circadian rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effect is mediated through the MT 2 melatonin receptor subtype within the circadian timing system. We conclude that the MT 2 melatonin receptor subtype is a novel therapeutic target for the development of subtype-selective analogs for the treatment of circadian sleep and mood-related disorders. THE HORMONE MELATONIN, produced and secreted from the pineal gland after a circadian rhythm high levels at night (1) regulates visual, circadian, and neuroendocrine functions through activation of melatonin receptors (2-8). The best characterized responses to melatonin in mammals are inhibition of dopamine release from retina (4, 9), modulation of neuronal firing (10, 11), and phase shifts of circadian rhythms (12, 13) through an action within the suprachiasmatic nucleus (SCN) 2 of the hypothalamus, site of the master biological clock. The competitive melatonin receptor antagonists luzindole and S20928 block phase shifts of circadian rhythms of electrical activity and neuronal firing within the SCN, suggesting that these physiological responses are mediated through activation of melatonin receptors (5, 9, 10, 14, 15). However, the melatonin receptor subtype (or subtypes) mediating these responses is unknown.
THE HORMONE MELATONIN, produced and secreted from the pineal gland after a circadian rhythm high levels at night (1) regulates visual, circadian, and neuroendocrine functions through activation of melatonin receptors (2) (3) (4) (5) (6) (7) (8) . The best characterized responses to melatonin in mammals are inhibition of dopamine release from retina (4, 9), modulation of neuronal firing (10, 11) , and phase shifts of circadian rhythms (12, 13) through an action within the suprachiasmatic nucleus (SCN) 2 of the hypothalamus, site of the master biological clock. The competitive melatonin receptor antagonists luzindole and S20928 block phase shifts of circadian rhythms of electrical activity and neuronal firing within the SCN, suggesting that these physiological responses are mediated through activation of melatonin receptors (5, 9, 10, 14, 15) . However, the melatonin receptor subtype (or subtypes) mediating these responses is unknown.
Melatonin activates membrane receptors and putative cytoplasmatic and nuclear sites to mediate a variety of physiological responses (4, 5) . In mammals, two molecularly distinct G-protein-coupled melatonin receptor subtypes have been identified [mt 1 (Mel 1a ), MT 2 (Mel 1b )] 3 (16, 17) . These melatonin receptor subtypes show 60% homology at the amino acid level (18, 19) and can be distinguished phar- 1 Correspondence: Department of Molecular Pharmacology and Biological Chemistry (S215), Northwestern University Medical School, 303 East Chicago Ave., Chicago, IL 60611-3008, USA. E-mail: dubo@nwu.edu. 2 Abbreviations: SCN, suprachiasmatic nucleus; MLT, melatonin; 4P-ADOT, 4-phenyl 2-acetamidotetraline; 4P-PDOT, 4-phenyl 2-propionamidotetraline; h, human; DIG, digoxigenin; PBS, phosphate-buffered saline; CT 10, circadian time 10 . 3 Here we use the official nomenclature and classification for melatonin receptors recently approved by the Nomenclature Committee of the International Union of Pharmacology (16, 17) . The denomination 'mt 1 ' corresponds to that of the recombinant melatonin receptor subtype previously known as Mel 1a , which does not show well-defined functional characteristics (18) . The mt 2 recombinant receptor, previously known as Mel 1b (19) , is referred to here as 'MT 2 ' because it has a defined function and was pharmacologically characterized in a native tissue (9). The prefix 'h' is used to refer to human receptors. macologically when using partial agonists and antagonists for melatonin receptors (4, 9) . The inhibition of dopamine release from rabbit retina is mediated through activation of MT 2 presynaptic heteroreceptors (9); the subtype that mediates phase shifts of circadian rhythms in the SCN, however, is not known. The mt 1 melatonin receptor was initially suggested to mediate circadian functions in mammals due to the high level of expression within the mammalian SCN (18) . However, while deletion of the mt 1 melatonin receptor in the C57BL/6 mouse blocks the melatonin-induced inhibition of neuronal firing in SCN slices, melatonin-mediated phase shifts of circadian firing rhythms are not impaired (11) . This phaseshifting effect of melatonin is pertussis toxin sensitive, suggesting the involvement of another, as yet unidentified G-protein-coupled receptor (11, 13) .
This study reports for the first time the expression of both mt 1 and MT 2 melatonin receptor mRNA within the SCN (using in situ hybridization) and the antagonism of melatonin-mediated phase advances of circadian activity rhythms (using MT 2 selective melatonin receptor antagonists) in the C3H/HeN mouse. We used the C3H/HeN mouse in these studies because it produces melatonin in the pineal gland (20) ; in this strain, melatonin phase shifts circadian activity rhythms with periods of sensitivity identical to those found in humans (12, 21) .
EXPERIMENTAL PROCEDURES

Drugs and chemicals
Melatonin and melatonin analogs were obtained from the following sources: melatonin was purchased from Regis Technologies, Inc. (Morton Grove, Ill.). 4-Phenyl 2-acetamidotetraline (4P-ADOT) and 4-phenyl 2-propionamidotetraline (4P-PDOT) were synthesized by the late Dr. Alan S. Horn (Department of Medicinal Chemistry, University of Groningen, The Netherlands) (22) and luzindole (2-benzyl-N-acetyltryptamine) was synthesized by Dr. Michael Flaugh (Eli Lilly and Company, Indianapolis, Ind.). All other chemicals were obtained from Sigma (St. Louis, Mo.).
The melatonin receptor antagonists luzindole, 4P-ADOT, and 4P-PDOT were screened on 50 binding assays to determine their affinity for G-protein-linked receptors (adenosine, a-adrenergic, b-adrenergic, dopamine, GABA A and B, glutamate, histamine, muscarinic, serotonin), channels (L and N calcium, chloride, NMDA, calcium-activated potassium/voltage insensitive), brain/gut peptides receptors (type 2 angiotensin II, cholecystokinin, neurokinin, neuropeptide Y, neurotensin, somatostatin, vasoactive intestinal peptide, vasopressin), growth factors/hormones receptors (atrial natriuretic peptide A, epidermal growth factor), neurotransmitter transporters (choline, dopamine, norepinephrine, serotonin), and second messengers (adenylate cyclase, inositol triphosphate, protein kinase C). None of the analogs produced significant inhibition of specific radioligand binding at a concentration of 10 mM. Screening was performed by Novascreen (Hanover, Mass.) as part of the National Institute of Mental Health Drug Discovery Program.
Cell lines
Stable cell lines expressing either the human recombinant mt 1 or mt 2 melatonin receptors were developed according to the method of lipofection by transfection of CHO-K1 cells (23) 
Circadian activity rhythms
Male C3H/HeN mice (5-6 wk old, Harlan, Indianapolis, Ind.) were housed in groups of five and maintained in temperature (22{1ЊC) and humidity controlled rooms. Food and water were provided ad libitum. Animals were maintained for 2 wk on a 12/12 light/dark cycle (300 lux at the level of the cage), then transferred to constant and complete darkness in individual cages (18130112 cm) equipped with activity wheels. All animal care and procedures were performed in accordance with institutional guidelines.
Rhythms of wheel-running activity were measured with a magnetic microswitch, which detected revolutions of the running wheel and was on line with an Epson 286 computer, as previously described (12) . Data were collected using the Dataquest III hardware and software package and analyzed with the assistance of TAU software (Mini-mitter, Sunriver, Oreg.).
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Mice were treated with vehicle, melatonin, and antagonists alone or in combination at circadian time 10 (CT 12: onset of activity). The exact circadian time of the pulse was determined after treatment from the onset of steady-state activity on the day of the pulse. Phase shifts were assessed by aligning the TAU guide by eye over the steady-state activity onsets of freerunning activity for 7 to 10 days before the pulse and from day 4 to 14 after the pulse. Transient shifts in activity onset for up to 3 days after the pulse were excluded. Phase shifts induced by treatment were measured in hours as the difference between the steady-state pre-and postpulse activity onsets, using the TAU program ruler. Differences between vehicle/melatonin and antagonist/melatonin treated groups were assessed for each melatonin dose by analysis of variance, followed by pairwise comparisons when indicated (GraphPad Prism, San Diego, Calif).
Mice were kept under constant darkness for 3 wk to stabilize the free-running activity rhythm. Mice were treated on three consecutive days at circadian time 10; CT 10 was estimated from the tau for each day. Each mouse was treated with both 1) vehicle (30% ethanol in 0.1 ml saline) or a melatonin antagonist dissolved in vehicle and 2) saline or melatonin dissolved in saline. These two daily treatments were carried out 10 min apart. Mice were treated with melatonin (0.3, 0.9, 3, 9, or 30 mg/mouse) and or one of the following antagonists: luzindole, 300 mg/mouse; 4P-ADOT, 90 mg/mouse; 4P-PDOT, 90 mg/mouse. Each mouse received one treatment every 3 wk and a total of four treatments. All treatments were performed under a dim red light (15 watt, Kodak 1A filter) with illuminance of less than 3 lux.
Receptor autoradiography
Male C3H/HeN mice free running in constant dark were killed at CT 10, and brains were dissected and processed for receptor autoradiography as described (26, 27) . Coronal brain sections (20 mm) were cut on a Reichert-Jung cryostat (Leica, Deerfield, Ill.) and thaw mounted onto gelatin-coated slides. Rostrocaudal brain sections containing the SCN were successively placed on a series of six slides so that sequential sections through the whole SCN could be analyzed. Slides were stored at ú80ЊC until processing. Slide-mounted sections were air dried for 15 min and then incubated with 2- ]iodomelatonin either without (total binding) or in the presence of the following agents: melatonin (1 mM), luzindole (100 nM and 10 mM), and 4P-ADOT (1 nM and 100 nM). Slides were rinsed twice for 15 min in ice-cold Tris-Ca buffer, followed by a rapid rinse in ice-cold distilled water to remove buffer salts.
Autoradiographic experiments were also run using TrisHCl buffer (50 mM) with 0.1% bovine serum albumin (pH 7.4) and shorter washes. Slide-mounted sections were air dried for 15 min and preincubated in the presence of vehicle (total binding) or melatonin (0.1 mM) or 4P-ADOT (1 and 100 nM) for 1 h. Sections were subsequently incubated for an additional hour with 2-[ 125 I]iodomelatonin (260 pM), vehicle, and drugs, as appropriate. Sections were rinsed either twice for 5 min or twice for 1 min in Tris-HCl buffer, followed by a rapid rinse in ice-cold distilled water.
Labeled sections were apposed to Kodak SB X-ray film for 7 days. Films were developed with Kodak D19 developer. Optical densities of autoradiograms were measured with a computer-based image analysis system (Bioquant System IV, R & M Biometrics, Nashville, Tenn.), using 14 C standards calibrated for use with 125 I as described previously (26, 28) .
In situ hybridization
Digoxigenin-labeled antisense and sense oligonucleotide probes were used to selectively hybridize with the mt 1 or MT 2 melatonin receptor mRNAs. The specificity of the oligonucleotide sequences was assessed by using alignment comparisons against the GenBank database (29). The oligonucleotide designed to hybridize with the mt 1 mRNA (TGAGGAGCACGTAGCAGAGGGAGTTCTTGC, 30 mer) corresponded to bases 431-460 of the mouse mt 1 melatonin receptor sequence (GenBank access number: U52222). The oligonucleotides designed to hybridize with the MT 2 mRNA (CGGGTCATATTCTAGAGACCCCACAAAGAAA, 31 mer) corresponded to bases (111-141) of the mouse MT 2 melatonin receptor partial sequence (GenBank Access number: U57554). These oligonucleotides showed little homology with other known sequences stored in the GenBank database. Antisense and sense oligonucleotide probes were synthesized at the Northwestern University Biotechnology Facility (Chicago, Ill.). Probes were tailed with digoxigenin (DIG) -tagged dATP using the DIG/Genius TM 6 oligonucleotide tailing kit (Boehringer-Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions. Briefly, each oligonucleotide probe was incubated with DIG-dATP in a 1:5 ratio in the presence of terminal transferase for 1 h at 37ЊC. Labeled oligonucleotides were purified by ethanol precipitation.
Male C3H/HeN mice free running in constant dark were killed at CT 10. Serial coronal mouse brain sections (30 mm) were cut on a Reichert-Jung cryostat (Leica) and thawmounted onto silane-coated slides. Sections were processed for nonradioactive in situ hybridization following a method previously reported, with slight modifications (30) . Sections were fixed in 4% paraformaldehyde in PBS (pH 7.4), rinsed twice in PBS, acetylated (10 min), dehydrated, delipidated, and air dried. Sections were then hybridized in the presence of 10-30 ng digoxigenin-labeled antisense or sense oligonucleotide probes selective for mt 1 or MT 2 receptor mRNAs. The hybridization solution contained 50% deionized formamide, 41 SSC, 10% dextran sulfate, 500 mg/ml sonicated and denatured salmon sperm DNA, 250 mg/ml yeast tRNA, 100 mM dithiothreitol, and 0.02% each of Ficoll, polyvinylpyrrolidone, and bovine serum albumin. Hybridization was carried out in a humid chamber overnight at 37ЊC. Nonspecific hybridization of the probes was minimized by washing the sections in 11 SSC at 50ЊC (4115 min), followed by four washes at room temperature (4115 min). The hybridization signal was detected using alkaline phosphatase conjugated anti-digoxigenin IgG (Boehringer-Mannheim), followed by the chromagen BCIP/NBT (Vector Lab, Burlingame, Calif.) in the presence of levamisole (1 mM).
RESULTS
Melatonin receptor-mediated physiological responses can be identified by using subtype-selective and specific antagonists. We first characterized the specificity of the putative melatonin receptor antagonists luzindole, 4P-ADOT, and 4P-PDOT for interaction with melatonin receptors (4, 9, 14, 31). They showed melatonin receptor specificity, as they did not compete for binding of 49 radioligands to receptors, channels, transporters, and second messengers (see Methods). However, these analogs showed various degrees of selectivity for the h MT 2 melatonin receptor subtype (9). ]iodomelatonin binding to the h MT 2 melatonin receptor. The K i affinity ratios for luzindole, 4P-ADOT, and 4P-PDOT showed that the compounds had 25-, 951-, and 1581-fold higher affinity for the h MT 2 than the h mt 1 melatonin receptor subtype (Fig. 1) .
The relative density of the mt 1 and MT 2 melatonin receptor subtypes in the C3H/HeN mouse SCN was assessed by competition of melatonin receptor antagonists for 2-[ (Fig. 1A) , defined 86 and 70% specific 2-[ 125 I]iodomelatonin binding to the SCN, respectively (Fig. 2B, D; Fig. 3 ). Concentrations of luzindole (100 nM) or 4P-ADOT (1 and 100 nM), which competed primarily for 2-[ 125 I]iodomelatonin to the MT 2 receptor (Fig. 1A, B) , did not reduce total binding in adjacent sections (Fig. 2C, E, F; Fig. 3 ). To decrease dissociation of 2-[ 125 I]iodomelatonin binding from a lower affinity melatonin receptor site (e.g., MT 2 , see K D values in legend of Fig. 1 ), washing times were reduced to either 2 or 10 min (32) . Although under these experimental conditions the background in the autoradiograms was high, the specific binding defined by melatonin (0.1 mM) after 10 min (94%) and 2 min (84%) washes was essentially identical (data not shown) to that defined when using longer washes (Fig. 3) . Similarly, 4P-ADOT (1 nM and 100 nM) did not compete for 2-[ We next asked whether the mRNA for the molecularly defined melatonin receptor subtypes mt 1 and MT 2 could be detected in the SCN of the C3H/HeN mouse by using in situ hybridization with digoxigenin-labeled antisense oligonucleotide probes. Selective antisense oligonucleotide probes for the mt 1 (Fig. 4A) and MT 2 (Fig. 4C ) melatonin receptor subtypes showed robust hybridization in the SCN, whereas hybridization of corresponding sense oligonucleotide probes to either receptor was negligible (Fig. 4B, D) . In SCN sections obtained within the intermediate level of the SCN, mt 1 mRNA was evenly distributed, with sparse expression in the medial crescent (Fig. 4A ). In contrast, the level of MT 2 mRNA expression in the SCN was higher in the medial crescent (Fig. 4C) .
In C3H/HeN mice, as in humans, melatonin administration for three consecutive days phase-advances circadian activity rhythms when given at the end of the subjective day (CT 10) (6, 12, 21). Figure  5 shows representative actograms of circadian rhythms of wheel running activity obtained in C3H/ HeN mice kept in constant dark. Treatment with vehicle, followed by saline administration for three consecutive days at CT 10, did not affect the rhythm of wheel running activity (Fig. 5) (12) . Melatonin administration at CT 10 induced advances in the phase of the circadian activity rhythms in a dose-dependent manner (0.3 to 30 mg/mouse) ( Fig. 5A and 6A ). The dose of melatonin inducing a half-maximal phase ad- 125 I]iodomelatonin in the absence (total binding) and presence of various agents [melatonin 1 mM (black), luzindole 100 nM and 10 mM (stippled), and 4P-ADOT 1 nM and 100 nM (striped)]. Binding was carried out at 25ЊC for 1 h as described. Sections were washed with Tris·Ca buffer twice every 15 min. P õ 0.001 when compared with total binding. vance (EC 50 ) was 0.72 mg/mouse with a maximal advance of 0.98 { 0.08 h (nÅ15) at 9 mg/mouse and a slope of 0.53 { 0.02 (Fig. 6A) .
To determine the involvement of mt 1 or MT 2 melatonin receptor subtypes on melatonin-induced phase advances, we assessed the ability of luzindole (showing 20 fold higher affinity for the MT 2 receptor) to block phase advances of circadian activity rhythms in C3H/HeN mice (12) . Luzindole (300 mg/ mouse, s.c.) did not affect the phase of the clock when administered alone at CT 10 to C3H/HeN mice free running in constant dark. However, luzindole competitively antagonized the phase advance induced by 0.9 and 3 mg/mouse of melatonin (Fig. 6B) . The two 4-phenyl amidotetraline antagonists, 4P-ADOT and 4P-PDOT, with 951-and 1580-fold higher affinity for the MT 2 melatonin receptor subtype, did not affect the phase of circadian activity rhythms when administered at 90 mg/mouse in combination with saline at CT 10 ( Fig. 5B and Fig. 6B ). These subtype-selective MT 2 melatonin receptor antagonists shifted the dose-response curve to the right as they significantly reduced the phase-shifting effect of 0.9 and 3 mg melatonin (Fig. 6B) . The selective MT 2 melatonin receptor antagonist 4P-PDOT also antagonized the phase shifts induced by 9 mg melatonin (Põ0.05, Fig. 6B ). We observed a statistically significant reduction in melatonin (0.3 mg/mouse) -induced phase advances at CT 10 with a lower dose of 4P-ADOT (30 mg/mouse) (data not shown).
DISCUSSION
By using subtype-selective MT 2 melatonin receptor antagonists, we demonstrated for the first time that melatonin modifies the phase of circadian activity rhythms in the C3H/HeN mice by activation of the MT 2 melatonin receptor subtype within the circadian timing system. Native MT 2 melatonin receptors in the SCN appear to be expressed at very low levels, as they were undetectable using 2-[ Representative wheel running activity actograms in vehicle, MLT, and 4P-ADOT-treated C3H/HeN mice. Circadian wheel running activity rhythms were recorded from C3H/HeN mice held in constant dark. Mice received two treatments a day on three consecutive days. Each day the first treatment was at CT 10 and the second treatment 10 min later. Arrows point to the circadian time (CT 10) on the first day of treatment. A) All mice were treated with vehicle (30% ethanol in 0.1 ml saline), followed by saline or melatonin (3 mg or 9 mg) 10 min later, as indicated. B) All mice were treated first with 4P-ADOT (90 mg/mouse), followed by saline or melatonin (3 mg or 9 mg) 10 min later.
sary to use subtype-selective and specific antagonists. The synthetic melatonin receptor antagonists used here-luzindole, 4P-ADOT, and 4P-PDOT-show specificity for melatonin receptors as they did not compete for binding of 49 radioligands to receptors, channels, transporters, and second messengers (see Methods). These analogs, however, competed for 2-[ 125 I]iodomelatonin binding to rabbit retina membranes and antagonized melatonin-mediated inhibition of dopamine release from this tissue (4, 9, 31). Luzindole, 4P-ADOT, and 4P-PDOT are high-affinity melatonin receptor antagonists (K B : 20, 1.6, and 0.3 nM, respectively), as they blocked the melatonin presynaptic heteroreceptor mediating inhibition of dopamine release in rabbit retina (4, 9, 14) . The affinity of these antagonists for the presynaptic melatonin heteroreceptor is almost identical to their affinity to compete for 2-[ 125 I]iodomelatonin binding to the recombinant h MT 2 melatonin receptor expressed in either COS-7 (9) or CHO cells (Fig. 1) . These results led to the conclusion that the presynaptic melatonin heteroreceptor of rabbit retina is the MT 2 melatonin receptor subtype (9).
The selectivity and specificity of melatonin receptor antagonists on the mt 1 (33) , COS-7 (9), or CHO cells (Fig. 1) . The nonselective melatonin receptor antagonist luzindole competes for 2-[ ]iodomelatonin binding to frozen sections of the C3H/HeN mouse SCN when using either short or long washes. The specific binding defined by 0.1 mM melatonin was identical when using long or short washes, which exclude binding of the radioligand to a lower affinity melatonin receptor (32) . These findings suggest that either the density of the MT 2 melatonin receptor protein in the C3H/HeN mouse SCN is below the limits of detection or that 2-[ The mRNA for both the mt 1 and MT 2 molecularly defined melatonin receptor subtypes could be detected in the SCN of the C3H/HeN mouse by using digoxigenin-labeled antisense oligonucleotide probes. Expression of mt 1 mRNA by in situ hybridization using riboprobes was previously demonstrated in the C3H/HeN mouse (26) and rat (18) SCN. However, this paper is the first report demonstrating expression of MT 2 mRNA in mammals when using in situ hybridization histochemistry. In the human retina and brain (as in the SCN) of the C57BL/6 mouse, the presence of MT 2 melatonin receptor mRNA expression has previously been observed by reverse transcription-polymerase chain reaction (11, 19) . The mt 1 melatonin receptor mRNA expresses in the mouse SCN after a circadian rhythm with high levels at night (26, 35) . Preliminary experiments suggest that in C3H/HeN mouse SCN, the expression of MT 2 mRNA is low in the middle of the light period and higher during the dark period of a 12/12 light/dark cycle (unpublished results). These results raise the possibility that the inability to detect the MT 2 of the mt 1 knockout mice is due to expression of this protein at times other that those selected in this and other studies (11) . Together, the results suggest that the expression of the MT 2 melatonin receptor mRNA is more widespread than previously thought. Indeed, we have demonstrated expression of both mt 1 and MT 2 mRNA in the human cerebellum and in rat caudal artery and superior cervical ganglia (unpublished results). In this study, melatonin administration for three consecutive days phase-advanced circadian activity rhythms in a dose-dependent manner. We originally demonstrated that in the C3H/HeN mouse, as in humans, melatonin administration for three consecutive days phase-shifts circadian activity rhythms, inducing either advances when given at the end of the subjective day (CT 10) or delays when given at the end of the subjective night (CT 22-CT 2) (6, 12, 21) . We have extended these observations and demonstrated that low doses of melatonin (0.9 to 9 mg/ mouse s.c.) are able to affect the phase of the clock. The half-maximal dose of melatonin to phase-advance circadian activity rhythms in the mouse was similar in magnitude to that necessary to induce entrainment in rats in vivo (36) . Similarly, in in vitro rodent SCN slices (11, 13, 15) melatonin advances circadian rhythms of electrical activity when applied at CT 10 with a potency (IC 50 Å9 pM) almost identical to that required for inhibition of calcium-dependent release of dopamine from rabbit retina (37) . These responses are blocked by luzindole, indicating activation of a melatonin receptor by melatonin (14, 15) . These results suggest that melatonin at both physiological and pharmacological doses acts within the circadian timing system to phase-shift the master biological clock.
Evidence suggests that the melatonin receptor (or receptors) mediating phase shifts of circadian activity rhythms is likely to be localized within the mammalian SCN. The phase advance of circadian rhythms of electrical activity elicited by melatonin in the rat SCN slice is blocked by luzindole (15) . In addition, melatonin inhibits metabolic activity in the rat SCN (38) and is unable to phase-shift circadian rhythms in SCN lesioned rats (2) . It follows that melatonin receptors in retina are unlikely to contribute to the phase shifting effects of the hormone since, in enucleated C3H/ HeN, the phase advances of circadian activity rhythms mediated by melatonin (30 mg/mouse) were similar in magnitude to those observed in control animals (data not shown). Similarly, in blind humans, melatonin entrains free-running rhythms (39) . Our data strongly suggest that, in the C3H/HeN mouse, activation of a melatonin receptor within the circadian timing system, possibly the SCN, mediates phase advances in circadian activity rhythms.
Specific and MT 2 subtype-selective antagonists for melatonin receptors blocked the melatonin-mediated phase advances of circadian activity rhythms in the C3H/HeN mouse. The MT 2 subtype-selective antagonists 4P-ADOT and 4P-PDOT were able to antagonize the phase shift in circadian activity rhythms elicited by melatonin at both 0.9 and 3 mg/mouse. Both antagonists (90 mg/mouse) were effective at doses lower than that of luzindole (300 mg/mouse), reflecting the higher affinity of the 4-phenyl 2-amidotetralines for the MT 2 receptor (9). These results suggest that activation of a G-protein-coupled melatonin receptor within the circadian timing system with pharmacological similarities to the h MT 2 and the presynaptic melatonin heteroceptor mediating inhibition of dopamine release in retina (9) phaseshifts circadian activity rhythms in the C3H/HeN mouse.
The MT 2 melatonin receptor appears to be emerging as the subtype involved in mediating important physiological functions by melatonin in the visual, vascular, and circadian systems ( Table 1) . Pharmacological studies using subtype-selective antagonists have demonstrated that the melatonin receptor involved in mediating inhibition of dopamine release from rabbit retina is the MT 2 subtype (9). The dual effect of melatonin on phenylephrine-mediated vasoconstriction in rat caudal artery appears to be mediated by activation of two distinct receptor subtypes: vasoconstriction by an mt 1 -like subtype and vasodilation by the MT 2 subtype (40) ( Table 1 ). In the mammalian SCN, activation of G-protein-coupled receptor subtypes by melatonin appears to mediate two distinct functional responses: acute inhibition of neuronal firing through the mt 1 subtype and time-dependent phase shifts of circadian rhythms through the / 382f 0015 Mp 1219 Tuesday Aug 18 04:58 PM LP-FASEB 0015 MT 2 subtype (10, 11; present data) ( Table 1) . Melatonin-mediated activation of the mt 1 subtype in the SCN and/or other limbic system areas may mediate somnogenic effects (11, 41) , whereas activation of the MT 2 subtype may be involved in the regulation of circadian rhythms. It thus follows that MT 2 -selective melatonin receptor agonists and/or antagonists may be used to treat disorders involving alterations in the phase of the circadian clock as observed in depression (8) , blindness (39) , delayed sleep phase syndrome (7), or after a rapid change in the light dark/cycle such as jet travel and shift work (7) . We conclude that the use of specific and subtype-selective mt 1 and MT 2 melatonin receptor antagonists will elucidate the functional role of melatonin in mammals and may prompt the development of subtypeselective analogs for treatment of insomnia and of circadian sleep and mood disorders.
